CL2014002019A1 - Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos. - Google Patents

Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.

Info

Publication number
CL2014002019A1
CL2014002019A1 CL2014002019A CL2014002019A CL2014002019A1 CL 2014002019 A1 CL2014002019 A1 CL 2014002019A1 CL 2014002019 A CL2014002019 A CL 2014002019A CL 2014002019 A CL2014002019 A CL 2014002019A CL 2014002019 A1 CL2014002019 A1 CL 2014002019A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
asic1 antibodies
asic1
antibodies
pharmaceutical
Prior art date
Application number
CL2014002019A
Other languages
English (en)
Inventor
Lynn Macdonald
Min Gao
Marc R Morra
Nicole M Alessandri-Haber
Michael L Lacroix-Fralish
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002019(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2014002019A1 publication Critical patent/CL2014002019A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014002019A 2012-01-31 2014-07-30 Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos. CL2014002019A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592837P 2012-01-31 2012-01-31
US201261644038P 2012-05-08 2012-05-08
US201261692925P 2012-08-24 2012-08-24

Publications (1)

Publication Number Publication Date
CL2014002019A1 true CL2014002019A1 (es) 2015-01-16

Family

ID=47666522

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002019A CL2014002019A1 (es) 2012-01-31 2014-07-30 Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.

Country Status (33)

Country Link
US (3) US9150648B2 (es)
EP (2) EP3453723B1 (es)
JP (1) JP6302844B2 (es)
KR (1) KR102111941B1 (es)
CN (1) CN104093738B (es)
AR (1) AR089852A1 (es)
AU (1) AU2013215254B2 (es)
CA (1) CA2862332C (es)
CL (1) CL2014002019A1 (es)
CO (1) CO7020877A2 (es)
CY (2) CY1121368T1 (es)
DK (2) DK2809681T3 (es)
EA (1) EA028647B1 (es)
ES (2) ES2707599T3 (es)
HR (2) HRP20190358T1 (es)
HU (2) HUE056335T2 (es)
IL (2) IL233410A0 (es)
IN (1) IN2014CN04645A (es)
JO (1) JO3547B1 (es)
LT (2) LT2809681T (es)
MX (1) MX358518B (es)
MY (1) MY168748A (es)
NZ (1) NZ626242A (es)
PH (1) PH12014501613A1 (es)
PL (2) PL3453723T3 (es)
PT (2) PT3453723T (es)
RS (2) RS62454B1 (es)
SG (1) SG11201403222UA (es)
SI (2) SI2809681T1 (es)
SM (1) SMT202100628T1 (es)
TW (1) TWI591073B (es)
UY (1) UY34603A (es)
WO (1) WO2013116296A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2809681T3 (en) 2012-01-31 2019-03-11 Regeneron Pharma ANTI-ASIC1 antibodies and uses thereof
JP2017513854A (ja) 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
KR20250099289A (ko) 2014-05-16 2025-07-01 아블린쓰 엔.브이. 개선된 면역글로불린 가변 도메인
HUE050007T2 (hu) 2014-05-16 2020-11-30 Ablynx Nv Immunglobulin variábilis domének
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105713089B (zh) * 2016-02-26 2019-08-06 上海科技大学 一种特异性抑制酸敏感离子通道i型的全人抗体
WO2018085441A1 (en) * 2016-11-01 2018-05-11 Berg Llc Filamin b binding proteins and uses thereof
EP3980456A4 (en) * 2019-06-04 2023-01-18 Shanghaitech University AFFINITY MATURING ANTI-ASIC1A ANTIBODIES
BR112022000216A2 (pt) 2019-07-11 2022-05-17 Memorial Sloan Kettering Cancer Center Anticorpos direcionados a dll3 e usos dos mesmos
WO2021012176A1 (en) * 2019-07-23 2021-01-28 Shanghaitech University Asic1 channel antagonist antibody
CA3154387A1 (en) * 2019-09-13 2021-03-18 Tri-Institutional Therapeutics Discovery Institute, Inc. Anti-cd371 antibodies and uses thereof
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
JP2024534892A (ja) * 2021-09-02 2024-09-26 メモリアル スローン ケタリング キャンサー センター 抗ｄｌｌ３抗体及びその使用
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2759373B1 (fr) 1997-02-11 2001-05-04 Centre Nat Rech Scient Nouveau canal cationique neuronal de mammifere sensible a l'acidite, son clonage et ses applications
ES2279583T3 (es) 1997-10-29 2007-08-16 Mcgill University Adn que codifica para un canal ionico regulado por protones humano y usos del mismo.
US6287859B1 (en) 1998-08-05 2001-09-11 Centre National De La Recherche Identification, functional expression and chromosal localization of a sustained human proton-gated cation channel
CA2304494A1 (en) 2000-04-20 2001-10-20 Philippe Seguela A novel heteromultimeric ion channel receptor and uses thereof
US6635432B1 (en) 2000-04-25 2003-10-21 University Of Iowa Research Foundation Peptide potentiation of acid-sensory ion channel in pain
US7132505B1 (en) 2001-05-10 2006-11-07 Centre National De La Recherche Scientifique - Cnrs Polypeptide inhibiting a proton-gated Na+ channel, a nucleic acid coding for such polypeptide and a method of manufacturing an ASIC1a channel blocker
CA2352702A1 (en) 2001-07-18 2003-01-18 Philippe Seguela Novel human proton gated ion channel
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CN1326879C (zh) * 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
US20030186860A1 (en) 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US20070197583A1 (en) 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
CA2538754A1 (en) 2003-09-11 2005-03-24 The Uab Research Foundation Inhibition of inward sodium currents in cancer
WO2005074923A1 (en) 2004-02-03 2005-08-18 Agt Biosciences Limited Methods and compositions
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp COMPOSITIONS AND METHOD FOR MODULATING CONTROLLED ION CHANNELS
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7192500B2 (en) 2004-04-30 2007-03-20 Kimberly-Clark Worldwide, Inc. Process for making a garment including an absorbent assembly
US8030442B2 (en) 2004-09-16 2011-10-04 Morehouse School Of Medicine Treatment of injury to the brain by inhibition of acid sensing ion channels
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
KR101203328B1 (ko) * 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
EP2078732B1 (en) * 2006-07-10 2015-09-16 Fujita Health University Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry
US8618113B2 (en) 2006-07-14 2013-12-31 Medical Research Council Treatment for demyelinating disease
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US7598039B2 (en) 2007-01-30 2009-10-06 Academia Sinica Treatment of insulin resistance
DK2137539T3 (da) 2007-04-03 2011-01-24 Ilegusavnid Genetics Resource Ct Minestry Of Social Affairs And Health Amolorid følsomme calciumkanaler forbundet med paniklidelser
CA2683145C (en) * 2007-04-27 2018-06-12 Katherine E. Lewis Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP2288922B1 (en) * 2008-05-08 2016-08-17 University of Utah Research Foundation Sensory receptors for chronic fatigue and pain and uses thereof
US20090291150A1 (en) 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
FR2932091B1 (fr) 2008-06-06 2012-12-28 Centre Nat Rech Scient Effets analgesiques de la toxine peptidique apetx2
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
GB0922434D0 (en) * 2009-12-22 2010-02-03 Ucb Pharma Sa antibodies and fragments thereof
CN102234316B (zh) * 2010-05-07 2014-01-29 中国人民解放军军事医学科学院毒物药物研究所 具有增强酸感受离子通道1a电流作用的多肽及其用途
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
DK2809681T3 (en) 2012-01-31 2019-03-11 Regeneron Pharma ANTI-ASIC1 antibodies and uses thereof

Also Published As

Publication number Publication date
EP2809681A1 (en) 2014-12-10
PT3453723T (pt) 2021-09-07
JP6302844B2 (ja) 2018-03-28
PH12014501613B1 (en) 2014-10-13
CA2862332A1 (en) 2013-08-08
LT2809681T (lt) 2019-02-11
CN104093738A (zh) 2014-10-08
NZ626242A (en) 2017-02-24
SMT202100628T1 (it) 2022-01-10
CO7020877A2 (es) 2014-08-11
EA028647B1 (ru) 2017-12-29
US20160002332A1 (en) 2016-01-07
US9150648B2 (en) 2015-10-06
DK3453723T3 (da) 2021-09-13
PT2809681T (pt) 2019-02-18
CY1124778T1 (el) 2022-11-25
MX358518B (es) 2018-08-24
ES2886123T3 (es) 2021-12-16
MX2014008541A (es) 2014-10-24
BR112014018651A2 (pt) 2017-07-04
HUE042531T2 (hu) 2019-07-29
PL2809681T3 (pl) 2019-05-31
IL233410A0 (en) 2014-08-31
HK1199269A1 (en) 2015-06-26
HRP20190358T1 (hr) 2019-04-05
CY1121368T1 (el) 2020-05-29
DK2809681T3 (en) 2019-03-11
RS62454B1 (sr) 2021-11-30
PH12014501613A1 (en) 2014-10-13
AU2013215254B2 (en) 2017-08-31
US20130195878A1 (en) 2013-08-01
IL254416B (en) 2018-03-29
SI2809681T1 (sl) 2019-04-30
HUE056335T2 (hu) 2022-02-28
PL3453723T3 (pl) 2022-01-03
UY34603A (es) 2013-07-31
ES2707599T3 (es) 2019-04-04
KR102111941B1 (ko) 2020-05-18
JP2015508063A (ja) 2015-03-16
TWI591073B (zh) 2017-07-11
IL254416A0 (en) 2017-11-30
KR20140125363A (ko) 2014-10-28
WO2013116296A1 (en) 2013-08-08
RS58439B1 (sr) 2019-04-30
MY168748A (en) 2018-11-30
CN104093738B (zh) 2018-05-18
EP3453723A2 (en) 2019-03-13
IN2014CN04645A (es) 2015-09-18
TW201335182A (zh) 2013-09-01
EP3453723B1 (en) 2021-08-11
US10513557B2 (en) 2019-12-24
EP2809681B1 (en) 2018-12-05
SG11201403222UA (en) 2014-07-30
EP3453723A3 (en) 2019-04-10
HRP20211541T1 (hr) 2021-12-24
LT3453723T (lt) 2021-09-10
US20180222976A1 (en) 2018-08-09
CA2862332C (en) 2021-05-18
JO3547B1 (ar) 2020-07-05
EA201491452A1 (ru) 2014-11-28
AR089852A1 (es) 2014-09-24
AU2013215254A1 (en) 2014-07-03
SI3453723T1 (sl) 2021-11-30

Similar Documents

Publication Publication Date Title
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
BR112015002790A2 (pt) anticorpos asgpr e usos dos mesmos.
CL2016000251A1 (es) Anticuerpos anti-activina y usos de los mismos
CL2014002616A1 (es) Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos.
CL2014002549A1 (es) Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
BR112015001459A2 (pt) anticorpos anti-kit e usos dos mesmos.
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
CL2015001924A1 (es) Anticuerpos anti-pdgfr-beta y usos relacionados.
CR20150380A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
CO7020859A2 (es) Anticuerpos anti-cd134 (ox40) y usos de los mismos
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
CO6821892A2 (es) Anticuerpos anti-angptl3 y usos de los mismos
CO7061078A2 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
PT2858671T (pt) Formulação de anticorpos
BR112014029403A2 (pt) conjugados, anticorpo e formulação farmacêutica
CL2015000027A1 (es) Anticuerpos e inmunoconjugados anti-cd22
BR112014028602A2 (pt) formulação líquida.
PT3079666T (pt) Composições farmacêuticas que contêm fumarato de dimetilo
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
PT2931313T (pt) Formulações de solução de anticorpos anti-il-23p19 modificados
BR112014026357A2 (pt) composição e sistema
DK2897594T3 (da) Farmaceutisk sammensætning